Windt Roland, Glaeske Gerd
Centre for Social Policy Research, University of Bremen, Bremen, Germany.
J Asthma. 2010 Aug;47(6):674-9. doi: 10.3109/02770900903556421.
The purpose of this study was to assess outcomes of a nationwide asthma disease management (DM) program in Germany. A retrospective observational study with propensity-score matching was performed using claims data of sickness funds exclusively. Effects were analyzed on the basis of a match of 317 program participants and nonparticipants with similar propensity score and age. Hospitalization or oral corticosteroid user rates were comparable in both groups, whereas there are significantly more subjects in the DM group with a prescription of an inhaled corticosteroid and fewer with a prescription of a cromolyn/reproterol combination. There are also less "doctor hoppers" in the DM group, defined as subjects with antiasthmatic drug prescriptions of at least three physicians. The results suggest that the impact of a nationwide disease management program for asthma is weak in respect of clinically relevant endpoints, but there are indications that medication in a DM program approximates asthma guidelines more closely.
本研究的目的是评估德国一项全国性哮喘疾病管理(DM)项目的效果。仅使用疾病基金的理赔数据进行了一项倾向得分匹配的回顾性观察研究。基于317名项目参与者和倾向得分及年龄相似的非参与者的匹配情况分析效果。两组的住院率或口服糖皮质激素使用率相当,而DM组中吸入糖皮质激素处方的受试者明显更多,色甘酸钠/瑞普特罗组合处方的受试者更少。DM组中“频繁更换医生者”(定义为至少有三位医生开具抗哮喘药物处方的受试者)也更少。结果表明,就临床相关终点而言,全国性哮喘疾病管理项目的影响较弱,但有迹象表明,DM项目中的用药更符合哮喘指南。